|Bid||0.00 x 800|
|Ask||0.00 x 800|
|Day's Range||164.74 - 169.56|
|52 Week Range||148.31 - 181.92|
|PE Ratio (TTM)||68.43|
|Beta (3Y Monthly)||1.02|
|Expense Ratio (net)||0.10%|
While millennials are doing a good job of saving in traditional ways, not parking their money in high-return investment options could be a potential mistake.
The U.S. equity rally is beginning to lose steam and investors should not expect markets to maintain their breakneck spurt of yesteryear. Nevertheless, traders may still find value in some battered sectors ...
As U.S. markets continue to wobble, investors who want to stay in the game can look to defensive sector-related ETFs for a more steady approach. “If the sell-off continues and it deepens, it’s going to ...
Even as the Democrats retook control of the House of Representatives and the Republicans maintained majority in the Senate, healthcare ETFs were also big winners following the 2018 Midterm Election results. ...
The Department of Justice issued a preliminary approval for CVS Pharmacy to acquire health care insurance company Aetna, possibly paving the way for transformative changes in the industry as cries for more affordable care emanating from consumers and regulators get louder. The Health Care Select Sector SPDR ETF (XLV) slid 0.42% as of 11:45 a.m. ET, Vanguard Health Care ETF (VHT) fell 0.54%, iShares US Medical Devices ETF (IHI) was down 1.21%, and iShares US Healthcare ETF (IYH) slid 0.55%. As part of the approval process, the DOJ set forth the condition that Aetna had to divest itself from its Medicare Part D drug plan, which it eventually sold to WellCare Health Plans for an undisclosed amount late last month.
Author Evan McCulloch Senior Vice President, Director of Research Franklin Equity Group® Portfolio Manager, Franklin Biotechnology Discovery Fund Since hitting an all-time high in July 2015, biotech stocks, as measured by the NASDAQ Biotechnology ...
Internet retail, small-cap and a health care stock fund are among SFMG Wealth Advisor's top ETF picks for the coming months.
The solid performance of the healthcare market in the first eight months of 2018 has created investment opportunities. These ETFs are poised to take advantage.
Johnson & Johnson (NYSE: JNJ), one of the world's largest healthcare companies, has underperformed the broader market in 2018. The company's stock is down 3.66% year to date (YTD), while the Standard and Poor's 500 index (S&P 500) is up roughly 7%. David Katz, chief investment officer at Matrix Asset Advisors, told Reuters, "We are much more upbeat about Johnson & Johnson today than we were six months ago.
The healthcare sector and related ETFs have been among the best performing defensive plays this year as strong earnings and potential Trump administration actions on drug pricing drew greater investment ...
The healthcare sector is one of this year's best-performing sectors and the group's recent strength is luring some investors to the related exchange traded funds. For healthcare ETFs, the good news is that the U.S. economy moving into the late-cycle phase, overall growth may slow and signs of an economic slowdown could pop up. “The $8.2 billion Vanguard Health Care ETF, known by its ticker VHT, had 1.6 million shares worth $272 million trade Monday, record one-day turnover for the fund.
With the healthcare sector recently outperforming technology, investors have been embracing healthcare exchange traded funds. The Health Care Select Sector SPDR (XLV) is the largest healthcare ETF by assets. XLV allocates about two-thirds of its combined weight to pharmaceuticals and biotechnology stocks.
The month of August started off on a shaky note for Wall Street with Fed imposed rising rate concerns and severity in the U.S.-Sino trade relations coming to the forefront.The Trump administration is reportedly considering a hike in tariffs from 10% to 20% on $200 billion worth of Chinese goods, after a 25% tariff announcement on $50 billion worth of goods.Source: Shutterstock
E*TRADE Financial Corporation today announced it has surpassed 250 commission-free ETFs with the addition of 46 ETFs from six providers to its Commission-Free ETF Pr
Merck’s (MRK) diabetes products include blockbuster drugs Januvia (sitagliptin) and Janumet (sitagliptin and metformin hydrochloride). Both drugs are used to control blood sugar levels in patients with diabetes.
Allergan’s (AGN) US General Medicines segment includes revenues from the US sales of its central nervous system products, women’s health products, gastrointestinal products, anti-infective products, and diversified brands.
The U.S. Commerce Department reported retail sales fell in February for the third month in a row, while the University of Michigan Consumer Sentiment Index4 jumped to a 14-year high and the Conference Board Consumer Confidence Index5 hovers near 17-year highs. This suggests that while times are good for most people, they have little desire to spend more in an economic expansion that is one of the longest on record. Households may save their gains from the Trump tax cuts, rather than spend in the economy, as the Commerce Department reports the savings rate ticked higher in February.